Mitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer's Disease

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Cabezas Opazo, Fabian A ^a   Vergara Pulgar, Katiana ^a   Pérez, María José ^a   Jara, Claudia ^a   Osorio Fuentealba, Cesar ^b   Quintanilla, Rodrigo A ^a  

^a UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^b UNIVERSIDAD METROPOLITANA DE CIENCIAS DE LA EDUCACIÓN   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BRAIN; DIAGNOSIS; MITOCHONDRIA; PATHOLOGY; PROTEINS;

AMYLOID PRECURSOR PROTEINS; ANTI-OXIDANT RESPONSE; MITOCHONDRIAL ACTIVITY; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL FUNCTION; NEUROFIBRILLARY TANGLES; PATHOGENIC MECHANISMS; THERAPEUTIC INTERVENTION;

NEURODEGENERATIVE DISEASES;

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; CATALASE; CYCLOPHILIN D; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 6; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRIAL PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; SYNAPTOPHYSIN; TAU PROTEIN; TRANSCRIPTION FACTOR NRF2; VOLTAGE DEPENDENT ANION CHANNEL 1;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; BIOENERGY; BIOGENESIS; BRAIN MITOCHONDRION; BRAIN NERVE CELL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; MEMBRANE DEPOLARIZATION; MEMBRANE FUSION; MEMORY DISORDER; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOPHAGY; MORPHOLOGY; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NERVOUS SYSTEM INFLAMMATION; NERVOUS SYSTEM INJURY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; ANIMAL; AXON; BRAIN; METABOLISM; MITOCHONDRION; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AXONS; BRAIN; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; TAU PROTEINS;

EID: 84937019697     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/509654     Document Type: Article

References (111)

1. S. M. Pritchard, P. J. Dolan, A. Vitkus, and G. V. W. Johnson, "The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics, " Journal of Cellular and Molecular Medicine, vol. 15, no. 8, pp. 1621-1635, 2011.
2. A. Serrano-Pozo, M. P. Frosch, E. Masliah, and B. T. Hyman, "Neuropathological alterations in Alzheimer disease, " Cold Spring Harbor Perspectives in Medicine, vol. 1, no. 1, Article ID a006189, 23 pages, 2011.
3. M. E. Murray, V. J. Lowe, N. R. Graff-Radford et al., "Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum, " Brain, vol. 138, no. 5, pp. 1370-1381, 2015.
4. A. Eckert, K. Schmitt, and J. Götz, "Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity, " Alzheimer's Research and Therapy, vol. 3, no. 3, article 15, 2011.
5. A. Johri andM. F. Beal, "Mitochondrial dysfunction in neurodegenerative diseases, " Journal of Pharmacology and Experimental Therapeutics, vol. 342, no. 3, pp. 619-630, 2012.
6. B. DuBoff, M. Feany, and J.Götz, "Why size matters-balancing mitochondrial dynamics in Alzheimer's disease, " Trends in Neurosciences, vol. 36, no. 6, pp. 325-335, 2013.
7. M. Cagalinec, D. Safiulina, M. Liiv et al., "Principles of the mitochondrial fusion and fission cycle in neurons, " Journal of Cell Science, vol. 126, no. 10, pp. 2187-2197, 2013.
8. D. C. Chan, "Mitochondrial fusion and fission in mammals, " Annual Review of Cell and Developmental Biology, vol. 22, pp. 79-99, 2006.
9. P. J. Crouch, S. M. E. Harding, A. R. White, J. Camakaris, A. I. Bush, and C. L. Masters, "Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease, " International Journal of Biochemistry & Cell Biology, vol. 40, no. 2, pp. 181-198, 2008.
10. P. S. Brookes, Y. Yoon, J. L. Robotham, M. W. Anders, and S.-S. Sheu, "Calcium, ATP, and ROS: a mitochondrial love-hate triangle, " American Journal of Physiology - Cell Physiology, vol. 287, no. 4, pp. C817-C833, 2004.
11. Z.-H. Sheng, "Mitochondrial trafficking and anchoring in neurons: new insight and implications, " Journal of Cell Biology, vol. 204, no. 7, pp. 1087-1098, 2014.
12. T. L. Schwarz, "Mitochondrial trafficking in neurons, " Cold SpringHarbor Perspectives in Biology, vol. 5, no. 6, 15pages, 2013.
13. Z.-X.Wang, L. Tan, and J.-T. Yu, "Axonal transport defects in Alzheimer's disease, " Molecular Neurobiology, vol. 51, no. 3, pp. 1309-1321, 2015.
14. G. Twig, A. Elorza, A. J. A. Molina et al., "Fission and selective fusion govern mitochondrial segregation and elimination by autophagy, "TheEMBOJournal, vol. 27, no. 2, pp.433-446, 2008.
15. D. C. Chan, "Mitochondria: dynamic organelles in disease, aging, and development, " Cell, vol. 125, no. 7, pp. 1241-1252, 2006.
16. L. M. Westrate, J. A. Drocco, K. R. Martin, W. S. Hlavacek, and J. P.MacKeigan, "Mitochondrial morphological features are associated with fission and fusion events, " PLoS ONE, vol. 9, no. 4, Article ID e95265, 15 pages, 2014.
17. M. T. Figge, A. S. Reichert, M. Meyer-Hermann, and H. D. Osiewacz, "Deceleration of fusion-fission cycles improves mitochondrial quality control during aging, " PLoS Computational Biology, vol. 8, no. 6, Article ID e1002576, 18 pages, 2012.
18. M. Liesa, M. Palacín, andA. Zorzano, "Mitochondrial dynamics in mammalian health and disease, " Physiological Reviews, vol. 89, no. 3, pp. 799-845, 2009.
19. R. J. Youle and A. M. van der Bliek, "Mitochondrial fission, fusion, and stress, " Science, vol. 337, no. 6098, pp. 1062-1065, 2012.
20. H. Chen and D. C. Chan, "Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases, " HumanMolecular Genetics, vol. 18, no. 2, pp.R169-R176, 2009.
21. P. H. Reddy, T. P. Reddy, M. Manczak, M. J. Calkins, U. Shirendeb, and P.Mao, "Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases, " Brain Research Reviews, vol. 67, no. 1-2, pp. 103-118, 2011.
22. E. Ingerman, E. M. Perkins, M. Marino et al., "Dnm1 forms spirals that are structurally tailored to fit mitochondria, " The Journal of Cell Biology, vol. 170, no. 7, pp. 1021-1027, 2005.
23. Y. Zhang and D. C. Chan, "Structural basis for recruitment of mitochondrial fission complexes by Fis1, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18526-18530, 2007.
24. O. C. Losón, Z. Song, H. Chen, and D. C. Chan, "Fis1, Mff, MiD49, andMiD51 mediateDrp1 recruitment in mitochondrial fission, "Molecular Biology of the Cell, vol. 24, no. 5, pp. 659-667, 2013.
25. H. Chen and D. C. Chan, "Emerging functions of mammalian mitochondrial fusion and fission, " Human Molecular Genetics, vol. 14, no. 2, pp. R283-R289, 2005.
26. Z. Song, M. Ghochani, J. M. McCaffery, T. G. Frey, and D. C. Chan, "Mitofusins and OPA1 mediate sequential steps in mitochondrialmembrane fusion, "Molecular Biology of the Cell, vol. 20, no. 15, pp. 3525-3532, 2009.
27. C. S. Palmer, L. D. Osellame, D. Stojanovski, and M. T. Ryan, "The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery, " Cellular Signalling, vol. 23, no. 10, pp. 1534-1545, 2011.
28. M. V. Alavi and N. Fuhrmann, "Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics, " Molecular Neurodegeneration, vol. 8, article 32, 2013.
29. H. Chen, J. M. McCaffery, and D. C. Chan, "Mitochondrial fusion protects against neurodegeneration in the cerebellum, " Cell, vol. 130, no. 3, pp. 548-562, 2007.
30. X.Wang, B. Su, H.-G. Lee et al., "Impaired balance of mitochondrial fission and fusion in Alzheimer's disease, " The Journal of Neuroscience, vol. 29, no. 28, pp. 9090-9103, 2009.
31. E.Motori, J. Puyal, N. Toni et al., "Inflammation-induced alteration of astrocyte mitochondrial dynamics requires autophagy for mitochondrial network maintenance, " Cell Metabolism, vol. 18, no. 6, pp. 844-859, 2013.
32. P. A. Trimmer and M. K. Borland, "Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement, " Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1101-1109, 2005.
33. X.Wang, B. Su, S. L. Siedlak et al., "Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation ofmitochondrial fission/fusion proteins, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 49, pp. 19318-19323, 2008.
34. H.Du, L. Guo, S. Yan, A. A. Sosunov, G. M. McKhann, and S. S. Yan, "Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 43, pp. 18670-18675, 2010.
35. Y. Hara, F. Yuk, R. Puri, W. G. M. Janssen, P. R. Rapp, and J. H. Morrison, "Presynaptic mitochondrial morphology in monkey prefrontal cortex correlates with working memory and is improved with estrogen treatment, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 1, pp. 486-491, 2014.
36. M. Manczak, M. J. Calkins, and P. H. Reddy, "Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage, " Human Molecular Genetics, vol. 20, no. 13, Article ID ddr139, pp. 2495-2509, 2011.
37. L.M. Ittner, Y. D. Ke, F.Delerue et al., "Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models, " Cell, vol. 142, no. 3, pp. 387-397, 2010.
38. A. Martorell-Riera, M. Segarra-Mondejar, J. P. Muñoz et al., "Mfn2 downregulation in excitotoxicity causes mitochondrial dysfunction and delayed neuronal death, " The EMBO Journal, vol. 33, no. 20, pp. 2388-2407, 2014.
39. J. Park, H. Choi, J.-S.Min et al., "Loss of mitofusin 2 links betaamyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells, " Journal of Neurochemistry, vol. 132, no. 6, pp. 687-702, 2015.
40. M. Manczak, T. S. Anekonda, E. Henson, B. S. Park, J. Quinn, and P. H. Reddy, "Mitochondria are a direct site of Abeta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression, " HumanMolecular Genetics, vol. 15, no. 9, pp. 1437-1449, 2006.
41. C. A. H. Petersen, N. Alikhani, H. Behbahani et al., "The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13145-13150, 2008.
42. J.-H. Cho and G. V. W. Johnson, "Glycogen synthase kinase 3β induces caspase-cleaved tau aggregation in situ, " The Journal of Biological Chemistry, vol. 279, no. 52, pp. 54716-54723, 2004.
43. S. Lee and T. B. Shea, "Caspase-mediated truncation of Tau potentiates aggregation, " International Journal of Alzheimer's Disease, vol. 2012, Article ID 731063, 7 pages, 2012.
44. G. B. Stokin, C. Lillo, T. L. Falzone et al., "Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease, " Science, vol. 307, no. 5713, pp. 1282-1288, 2005.
45. D.-F. Suen, K. L. Norris, and R. J. Youle, "Mitochondrial dynamics and apoptosis, " Genes & Development, vol. 22, no. 12, pp. 1577-1590, 2008.
46. R. A. Quintanilla, T. A. Matthews-Roberson, P. J. Dolan, and G. V. W. Johnsion, "Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease, " The Journal of Biological Chemistry, vol. 284, no. 28, pp. 18754-18766, 2009.
47. R. A. Quintanilla, P. J. Dolan, Y. N. Jin, and G. V. W. Johnson, "Truncated tau and Aβ cooperatively impair mitochondria in primary neurons, " Neurobiology of Aging, vol. 33, no. 3, pp. 619.e25-619.e35, 2012.
48. M. Manczak and P. H. Reddy, "Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage, " Human Molecular Genetics, vol. 21, no. 11, pp. 2538-2547, 2012.
49. R.A.Quintanilla, R. vonBernhardi, J. A.Godoy, N. C. Inestrosa, and G. V. W. Johnson, "Phosphorylated tau potentiates Aβ-induced mitochondrial damage in mature neurons, " Neurobiology of Disease, vol. 71, no. 1, pp. 260-269, 2014.
50. P.Bubber, V. Haroutunian, G. Fisch, J. P. Blass, andG.E.Gibson, "Mitochondrial abnormalities in Alzheimer brain: mechanistic implications, " Annals of Neurology, vol. 57, no. 5, pp. 695-703, 2005.
51. G. Aliev, H. H. Palacios, B. Walrafen, A. E. Lipsitt, M. E. Obrenovich, and L.Morales, "Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease, " The International Journal of Biochemistry & Cell Biology, vol. 41, no. 10, pp. 1989-2004, 2009.
52. S.Hauptmann, I. Scherping, S. Dröse et al., "Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice, " Neurobiology of Aging, vol. 30, no. 10, pp. 1574-1586, 2009.
53. V. Rhein, X. Song, A. Wiesner et al., "Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 47, pp. 20057-20062, 2009.
54. R. Duara, C. Grady, J. Haxby et al., "Positron emission tomography in Alzheimer's disease, " Neurology, vol. 36, no. 7, pp. 879-887, 1986.
55. P. Mao and P. H. Reddy, "Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics, " Biochimica et Biophysica Acta, vol. 1812, no. 11, pp. 1359-1370, 2011.
56. C. S. Casley, L. Canevari, J. M. Land, J. B. Clark, and M. A. Sharpe, "β-amyloid inhibits integrated mitochondrial respiration and key enzyme activities, " Journal of Neurochemistry, vol. 80, no. 1, pp. 91-100, 2002.
57. P. J. Crouch, R. Blake, J. A.Duce et al., "Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-β1-42, " Journal of Neuroscience, vol. 25, no. 3, pp. 672-679, 2005.
58. C. S.Casley, J.M. Land, M.A. Sharpe, J. B. Clark, M. R. Duchen, and L. Canevari, "β-Amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons, " Neurobiology of Disease, vol. 10, no. 3, pp. 258-267, 2002.
59. J. K. Parks, T. S. Smith, P. A. Trimmer, J. P. Bennett Jr., and W. D. Parker Jr., "Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxidesynthase mechanisms, and inhibit complex IV activity and induce amitochondrial permeability transition in vitro, " Journal of Neurochemistry, vol. 76, no. 4, pp. 1050-1056, 2001.
60. A. M. Aleardi, G. Benard, O. Augereau et al., "Gradual alteration of mitochondrial structure and function by β-amyloids: importance ofmembrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release, " Journal of Bioenergetics and Biomembranes, vol. 37, no. 4, pp. 207-225, 2005.
61. S. M. Cardoso, R. H. Swerdlow, and C. R. Oliveira, "Induction of cytochrome c-mediated apoptosis by amyloid β 25-35 requires functionalmitochondria, " Brain Research, vol. 931, no.2, pp. 117-125, 2002.
62. M.E.Clementi, S.Marini, M. Coletta, F.Orsini, B.Giardina, and F.Misiti, "Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35, " FEBS Letters, vol. 579, no. 13, pp. 2913-2918, 2005.
63. K. Leuner, T. Schütt, C. Kurz et al., "Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation, " Antioxidants & Redox Signaling, vol. 16, no. 12, pp. 1421-1433, 2012.
64. H. Xie, J. Guan, L. A. Borrelli, J. Xu, A. Serrano-Pozo, and B. J. Bacskai, "Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model, " The Journal of Neuroscience, vol. 33, no. 43, pp. 17042-17051, 2013.
65. E. Trushina, E. Nemutlu, S. Zhang et al., "Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress inmousemodels of familial alzheimer's disease, " PLoS ONE, vol. 7, no. 2, Article ID e32737, 17 pages, 2012.
66. R. A. Quintanilla, J. A. Orellana, and R. von Bernhardi, "Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress, " Archives ofMedical Research, vol. 43, no. 8, pp. 632-644, 2012.
67. S. M. de la Monte and J. R. Wands, "Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease, " Journal of Alzheimer's Disease, vol. 9, no. 2, pp. 167-181, 2006.
68. J. Yao, R. W. Irwin, L. Zhao, J. Nilsen, R. T. Hamilton, and R. D. Brinton, "Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14670-14675, 2009.
69. D. C. David, S. Hauptmann, I. Scherping et al., "Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice, "The Journal of Biological Chemistry, vol. 280, no. 25, pp. 23802-23814, 2005.
70. W. M. Saxton and P. J. Hollenbeck, "The axonal transport of mitochondria, " Journal of Cell Science, vol. 125, no. 9, pp. 2095-2104, 2012.
71. J. E. Duncan and L. S. B. Goldstein, "The genetics of axonal transport and axonal transport disorders, " PLoS Genetics, vol. 2, no. 9, pp. 1275-1284, 2006.
72. L. L. Lackner, "Shaping the dynamic mitochondrial network, " BMC Biology, vol. 12, no. 1, article 35, 2014.
73. S. Millecamps and J.-P. Julien, "Axonal transport deficits and neurodegenerative diseases, " Nature Reviews Neuroscience, vol. 14, no. 3, pp. 161-176, 2013.
74. Z. H. Sheng and Q. Cai, "Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration, " Nature Reviews Neuroscience, vol. 13, no. 2, pp. 77-93, 2012.
75. M. Y. Lin and Z. H. Sheng, "Regulation of mitochondrial transport in neurons, " Experimental Cell Research, vol. 334, no. 1, pp. 35-44, 2015.
76. Y. Chen and Z.-H. Sheng, "Kinesin-1-syntaphilin coupling mediates activity-dependent regulation of axonal mitochondrial transport, " The Journal of Cell Biology, vol. 202, no. 2, pp. 351-364, 2013.
77. M. Dubey, P. Chaudhury, H. Kabiru, and T. B. Shea, "Tau inhibits anterograde axonal transport and perturbs stability in growing axonal neurites in part by displacing kinesin cargo: neurofilaments attenuate tau-mediated neurite instability, " Cell Motility and the Cytoskeleton, vol. 65, no. 2, pp. 89-99, 2008.
78. K. Iijima-Ando, M. Sekiya, A. Maruko-Otake et al., "Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1, " PLoS Genetics, vol. 8, no. 8, Article ID e1002918, 2012.
79. P. H. Reddy, "Abnormal tau, mitochondrial dysfunction, impaired axonal transport ofmitochondria, and synaptic deprivation in Alzheimer's disease, " Brain Research, vol. 1415, pp. 136-148, 2011.
80. M. J. Calkins and P. H. Reddy, "Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons, " Biochimica et BiophysicaActa, vol. 1812, no. 4, pp. 507-513, 2011.
81. K. A. Vossel, K. Zhang, J. Brodbeck et al., "Tau reduction prevents Aβ-induced defects in axonal transport, " Science, vol. 330, no. 6001, p. 198, 2010.
82. K.A.Vossel, J. C. Xu, V.Fomenko et al., "Tau reductionprevents Aβ-induced axonal transport deficits by blocking activation of GSK3, " The Journal of Cell Biology, vol. 209, no. 3, pp. 419-433, 2015.
83. L. Guo, H. Du, S. Yan et al., "Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer's neurons, " PLoS ONE, vol. 8, no. 1, Article ID e54914, 13 pages, 2013.
84. M. J. Calkins, M. Manczak, P. Mao, U. Shirendeb, and P. H. Reddy, "Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease, " Human Molecular Genetics, vol. 20, no. 23, pp. 4515-4529, 2011.
85. M. Llorens-Martín, G. López-Doménech, E. Soriano, and J. Avila, "GSK3β is involved in the relief of mitochondria pausing in a Tau-dependent manner, " PLoS ONE, vol. 6, no. 11, Article ID e27686, 8 pages, 2011.
86. K. Shahpasand, I. Uemura, T. Saito et al., "Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease, " The Journal of Neuroscience, vol. 32, no. 7, pp. 2430-2441, 2012.
87. N. E. LaPointe, G.Morfini, G. Pigino et al., "Theamino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity, " Journal of Neuroscience Research, vol. 87, no. 2, pp. 440-451, 2009.
88. K. J. Kopeikina, G. A. Carlson, R. Pitstick et al., "Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain, " The American Journal of Pathology, vol. 179, no. 4, pp. 2071-2082, 2011.
89. T. Sun, H. Qiao, P.-Y. Pan, Y. Chen, and Z.-H. Sheng, "Motile axonalmitochondria contribute to the variability of presynaptic strength, " Cell Reports, vol. 4, no. 3, pp. 413-419, 2013.
90. N. Ohnoa, H. Chianga, D. J. Mahada et al., "Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 27, pp. 9953-9958, 2014.
91. P. M. Rappold, M. Cui, J. C. Grima et al., "Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo, " Nature Communications, vol. 5, article 5244, 2014.
92. P. H. Reddy, "Inhibitors ofmitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction, " Journal of Alzheimer's Disease, vol. 40, no. 2, pp. 245-256, 2014.
93. C. Stockburger, C. Kurz, K. A. Koch, S. H. Eckert, K. Leuner, andW. E.Müller, "Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam, " Biochemical Society Transactions, vol. 41, no. 5, pp. 1331-1334, 2013.
94. T. Yu, B. S. Jhun, and Y. Yoon, "High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission, " Antioxidants & Redox Signaling, vol. 14, no. 3, pp. 425-437, 2011.
95. X. Gan, S. Huang, L. Wu et al., "Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell, " Biochimica et Biophysica Acta, vol. 1842, no. 2, pp. 220-231, 2014.
96. M.Manczak, T.Sheiko, W. J. Craigen, andP.H.Reddy, "Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies, " Journal of Alzheimer's Disease, vol. 37, no. 4, pp. 679-690, 2013.
97. S. Chen, G. C. Owens, H. Makarenkova, and D. B. Edelman, "HDAC6 regulates mitochondrial transport in hippocampal neurons, " PLoS ONE, vol. 5, no. 5, Article ID e10848, 2010.
98. N. Govindarajan, P. Rao, S. Burkhardt et al., "Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease, " EMBO Molecular Medicine, vol. 5, no. 1, pp. 52-63, 2013.
99. M. J. Calkins, M. Manczak, and P. H. Reddy, "Mitochondriatargeted antioxidant SS31 prevents Amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease, " Pharmaceuticals, vol. 5, no. 10, pp. 1103-1119, 2012.
100. P. Mao, M. Manczak, M. J. Calkins et al., "Mitochondriatargeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension, " HumanMolecular Genetics, vol. 21, no. 13, Article IDdds128, pp. 2973-2990, 2012.
101. A. K. Kondadi, S. Wang, S. Montagner et al., "Loss of the m-AAA protease subunit AFG3L2 causesmitochondrial transport defects and tau hyperphosphorylation, " The EMBO Journal, vol. 33, no. 9, pp. 1011-1026, 2014.
102. B. Sheng, X.Wang, B.Suet al., "Impairedmitochondrialbiogenesis contributes to mitochondrial dysfunction in Alzheimer's disease, " Journal of Neurochemistry, vol. 120, no. 3, pp. 419-429, 2012.
103. J. St-Pierre, S. Drori, M. Uldry et al., "Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators, " Cell, vol. 127, no. 2, pp. 397-408, 2006.
104. R. A. Quintanilla, E. Utreras, and F. A. Cabezas-Opazo, "Role of PPARγ in the differentiation and function of neurons, " PPAR Research, vol. 2014, Article ID 768594, 9 pages, 2014.
105. E. E. Vomhof-DeKrey and M. J. Picklo, "The Nrf2-antioxidant response element pathway: a target for regulating energy metabolism, " The Journal of Nutritional Biochemistry, vol. 23, no. 10, pp. 1201-1206, 2012.
106. K. Kanninen, R. Heikkinen, T. Malm et al., "Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 38, pp. 16505-16510, 2009.
107. C. P. Ramsey, C. A. Glass, M. B.Montgomery et al., "Expression of Nrf2 in neurodegenerative diseases, " Journal of Neuropathology and Experimental Neurology, vol. 66, no. 1, pp. 75-85, 2007.
108. K.Kanninen, T.M.Malm, H. K. Jyrkkänen et al., "Nuclear factor erythroid 2-related factor 2 protects against beta amyloid, " Molecular and Cellular Neuroscience, vol. 39, no. 3, pp. 302-313, 2008.
109. C. J. Wruck, M. E. Götz, T. Herdegen, D. Varoga, L.-O. Brandenburg, and T. Pufe, "Kavalactones protect neural cells against amyloid β peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation, " Molecular Pharmacology, vol. 73, no. 6, pp. 1785-1795, 2008.
110. C. Jo, S. Gundemir, S. Pritchard, Y. N. Jin, I. Rahman, and G. V. W. Johnson, "Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52, " Nature Communications, vol. 5, article 3496, 2014.
111. H. Manji, T. Kato, N. A. Di Prospero et al., "Impaired mitochondrial function in psychiatric disorders, " Nature Reviews Neuroscience, vol. 13, no. 5, pp. 293-307, 2012.